Marimed (MRMD) Preferred Stock Liabilities (2020 - 2026)

Marimed (MRMD) has reported Preferred Stock Liabilities for 7 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Preferred Stock Liabilities fell 52.92% year-over-year to $6.9 million in Q2 2026; TTM through Jun 2026 was $6.9 million, a 52.92% decrease from a year earlier, with the FY2025 full-year figure at $14.7 million, down 22.5% from the prior year.
• Preferred Stock Liabilities was $6.9 million for Q2 2026 at Marimed, roughly flat from $6.9 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $37.7 million in Q1 2022 and troughed at $6.9 million in Q1 2026.
• A 5-year average of $22.1 million and a median of $19.0 million in 2023 frame the typical range for Preferred Stock Liabilities.
• Across the five-year window, Preferred Stock Liabilities changed 0.0% in 2022 and plunged 52.92% in 2026, its largest moves.
• Over 5 years, Preferred Stock Liabilities stood at $37.7 million in 2022, then tumbled by 49.64% to $19.0 million in 2023, then changed by 0.0% to $19.0 million in 2024, then slipped by 22.5% to $14.7 million in 2025, then slumped by 52.92% to $6.9 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $6.9 million (Q2 2026), $6.9 million (Q1 2026), and $14.7 million (Q4 2025), per Business Quant data.